scholarly journals Vitamin D in Rheumatic Diseases: Interpretation and Significance

2019 ◽  
Author(s):  
Binit Vaidya ◽  
Shweta Nakarmi
Keyword(s):  
Vitamin D ◽  
Rheumatic Diseases

scholarly journals POS1067 BASELINE VITAMIN D LEVELS AND DISEASE ACTIVITY AND RESPONSE IN PORTUGUESE PATIENTS WITH PSORIATIC ARTHRITIS UNDER bMDARD: DOES IT MAKE A DIFFERENCE?

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 812.1-812
Author(s):  
F. Oliveira Pinheiro ◽  
B. M. Fernandes ◽  
S. Garcia ◽  
M. Rato ◽  
D. Fonseca ◽  
...  
Keyword(s):  
Vitamin D ◽  
Psoriatic Arthritis ◽  
Disease Activity ◽  
Rheumatic Diseases ◽  
Response To Therapy ◽  
Response Criteria ◽  
National Database ◽  
Vitamin D Levels ◽  
Activity Measures ◽  
Disease Activity Measures

Background:There is growing evidence that vitamin D [25(OH)D]) plays an important role in maintaining skeletal health and modulating the immune system. Epidemiological data indicate that vitamin D deficiency is common in immune-mediated rheumatic diseases, especially in rheumatoid arthritis, but there is little data regarding its association with disease activity and response to therapy in patients with psoriatic arthritis (PsA) under bDMARD therapy.Objectives:We aimed to assess whether 25(OH)D basal levels correlate with disease activity and clinical response to the first bDMARD, at 6 and 12 months of therapy, in a monocentric cohort of patients with PsA.Methods:This retrospective study was carried out on PsA patients from a Rheumatology department of a tertiary hospital, fulfilling CASPAR criteria and registered in our national database (Reuma.pt), who started the first bDMARD since 2008. Demographic, clinical and laboratory criteria were evaluated at 0, 6 and 12 months of biologic therapy. Disease activity was assessed using CDAI, SDAI, DAS28(4V), BASDAI, ASDAS, DAPSA and the response was measured using the EULAR, BASDAI50, ASDAS, ASAS, ACR and PsARC responses. Correlations were made between absolute serum levels of 25(OH)D and continuous variables, as well as associations between different vitamin D cutoffs and disease activity measures and response criteria. Multiple linear and logistic regression analyses were performed to determine whether vitamin D is a predictor of disease activity and therapeutic response.Results:We included 81 patients, 41 (50.6%) females; with a mean age of 48.0±11.7 years, a mean disease duration of 9.5±7.4 years and a mean body mass index of 28.4±5.2 kg/m2. Thirteen (16.0%) were smokers. The mean 25(OH)D basal level was 25.5±13.2 ng/ml, 21 (25.9%) had 25(OH)D basal levels ≥30 ng/mL and 31 (38.3%) ≤20 ng/mL. Sixty-two patients (76.5%) were under csDMARD therapy. Golimumab (29, 35,8%), etanercept (28, 34.6%) and adalimumab (10, 12.3%) were the most frequently prescribed bDMARDs. There were only very weak, albeit positive, correlations between 25(OH)D levels and measures of disease activity. The BASDAI50 response at 6 months was associated with higher basal 25(OH)D levels (29.5±14.5 vs 21.5±10.2 ng/mL, p = 0.013); the ASAS20 (33.9±15.9 vs 24.2±12.8 ng/mL; p = 0.023), ASAS40 (31.9±14.6 vs 25.0±13.8 ng/mL; p = 0.023) and ASAS70 (47.0±4.2 vs 26.6±14.2; p = 0.027) responses at 12 months were associated with higher basal levels of 25(OH)D; basal 25(OH)D levels were ≥ 30ng/mL in a significantly higher proportion of patients who achieved CDAI (38.9% vs 10.5%; p = 0.027) and SDAI (38.9% vs 7.7%; p = 0.008) remission and ASDAS disease inactive (29.4% vs 7.3%; p = 0.040) at 1 year. In the regression models, basal levels of 25(OH)D were found to be predictors of good EULAR responders (OR 1.315, 1.017-1.213 95% CI; p = 0.037) at 6 months. Basal levels of 25(OH)D were not significantly different in patients who discontinued bDMARD and no significant correlations or associations were identified regarding more specific PsA activity measures, such as DAPSA and PsARC, nor were they predictive of these responses.Conclusion:We can conclude that there is a global trend for an association between higher levels of vitamin D and lower measures of disease activity and better therapeutic responses to the first biologic. It was possible to find statistically significant associations with some disease activity measures and response criteria that, although primarily designed for other rheumatic diseases, are often used in PsA.Disclosure of Interests:None declared.

Lower concentration of vitamin D is associated with lower DAS28 and VAS-pain scores in patients with inflammatory rheumatic diseases treated with infliximab: a pilot study

2020 ◽  
Vol 40 (9) ◽  
pp. 1455-1461
Author(s):  
Marijana Miler ◽  
Nora Nikolac Gabaj ◽  
Simeon Grazio ◽  
Antonio Vahtarić ◽  
Alen Vrtarić ◽  
...  
Keyword(s):  
Vitamin D ◽  
Pilot Study ◽  
Rheumatic Diseases ◽  
Inflammatory Rheumatic Diseases ◽  
Pain Scores

scholarly journals Vitamin D deficiency in chronic inflammatory rheumatic diseases: results of the cardiovascular in rheumatology [CARMA] study

2015 ◽  
Vol 17 (1) ◽  
Author(s):  
Ana Urruticoechea-Arana ◽  
◽  
María A. Martín-Martínez ◽  
Santos Castañeda ◽  
Carlos A. Sanchez Piedra ◽  
...  
Keyword(s):  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Rheumatic Diseases ◽  
Inflammatory Rheumatic Diseases ◽  
Chronic Inflammatory Rheumatic Diseases

Vitamin D status in children with rheumatic diseases

2018 ◽  
Vol 13 (5) ◽  
pp. 18-23
Author(s):  
N.S. Podchernyaeva ◽  
◽  
N.A. Geppe ◽  
A.A. Ivina ◽  
O.V. Shpitonkova ◽  
...  
Keyword(s):  
Vitamin D ◽  
Rheumatic Diseases ◽  
Vitamin D Status

Vitamin D in autoimmune rheumatic diseases: A view inside gender differences

2017 ◽  
Vol 117 ◽  
pp. 228-241 ◽  
Author(s):  
Massimiliano Vasile ◽  
Clarissa Corinaldesi ◽  
Cristina Antinozzi ◽  
Clara Crescioli
Keyword(s):  
Gender Differences ◽  
Vitamin D ◽  
Rheumatic Diseases ◽  
Autoimmune Rheumatic Diseases

Vitamin D and autoimmune rheumatic diseases

2011 ◽  
Vol 30 (3) ◽  
pp. 443-444 ◽  
Author(s):  
Paola Caramaschi ◽  
Alessandra Dalla Gassa ◽  
Orazio Ruzzenente ◽  
Alessandro Volpe ◽  
Viviana Ravagnani ◽  
...  
Keyword(s):  
Vitamin D ◽  
Rheumatic Diseases ◽  
Autoimmune Rheumatic Diseases

scholarly journals AB0767 PATIENTS WITH RHEUMATOID ARTHRITIS HAVE A LOWER BONE DENSITY THAN PATIENTS WITH PSORIATIC ARTHRITIS

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1681.1-1682
Author(s):  
D. Freier ◽  
E. Wiebe ◽  
R. Biesen ◽  
T. Buttgereit ◽  
S. Hermann ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Vitamin D ◽  
Psoriatic Arthritis ◽  
Bone Density ◽  
Rheumatic Diseases ◽  
Genetic Factors ◽  
Disease Duration ◽  
Mineral Density ◽  
Long Term Treatment ◽  
Density Values

Background:Osteoporosis is a skeletal disease characterized by the loss of bone density resulting in an increased fracture risk. Female sex, advanced age, Caucasian ancestry, previous history of fractures, menopause and certain genetic factors predispose for osteoporosis. In addition, recent studies could prove that chronic inflammatory diseases such as Rheumatoid Arthritis (RA) and long-term treatment with higher doses of glucocorticoids (GCs) represent independent risk factors for the development of osteoporosis. On the other hand, the intake of vitamin D, a calcium-rich diet and physical exercise can be protective. Data describing the prevalence of osteoporosis in patients with other rheumatic diseases like psoriatic arthritis (PsA) are lacking.Objectives:We compared the prevalence of osteopenia and osteoporosis in patients with RA and PsA, respectively, based on data obtained from our ongoing prospective monocentric study Rh-GIOP investigating glucocorticoid (GC)-induced osteoporosis in patients with different rheumatic diseases (NCT02719314).Methods:Bone mineral density data measured by dual x-ray absorptiometry (DXA) in patients with PsA (n=92) were compared with data measured in 92 age- and gender-matched patients with RA. The results were analysed with respect to clinical and laboratory parameters such as data on GC treatment (frequency, duration defined as start of treatment until timepoint of measurement, actual and cumulative dose), csDMARD and bDMARD (including as well tsDMARDs) therapy, serological parameters (Vitamin D, alkaline phosphatase, calcium, inflammatory markers and rheumatoid factor) and functional status (e.g. Health Assessment Questionnaire (HAQ), sporting activities). Statistical analyses were performed descriptively using mean and standard deviation, t-tests for metric variables, and chi-square tests for nominal variables. For subgroup analyses with less than 30 patients per group, tests for non-normally distributed data were used due to the lower test power.Results:RA patients showed significantly lower means of bone density values (minimal T-score, p=0.03) than PsA patients leading to a higher frequency of osteopenic bone densities (p<0.005). However, no differences in the frequency of osteoporotic bone densities could be detected. PsA patients reported a significantly longer disease duration and a higher current GC dosage. In contrast, the frequency of current GC intake was higher in RA patients. Although the calcium intake was higher in the RA group, neither blood levels of calcium and vitamin D, nor the cumulative GC dose (GCCD) or duration of GC therapy could indicate a causal relationship for the differences observed in bone density values between the two groups. The frequency of csDMARD therapy did not differ significantly between PsA and RA patients while the frequency of bDMARD therapy was higher in the PsA group (p=0.04).Conclusion:The lower bone density in RA patients seems not to be fully explained by higher GCCD, disease duration or higher levels of inflammation. However, RA patients had a higher frequency of current GC intake. Additionally, differences in bone density between the two groups could be related to the higher number of bDMARD therapies in PsA patients, but further investigations like multivariate analyses with higher numbers of patients are necessary. Furthermore there is more need for research on possible molecular and genetic factors in PsA, which are protecting from low bone density.Disclosure of Interests:Desiree Freier: None declared, Edgar Wiebe: None declared, Robert Biesen: None declared, Thomas Buttgereit: None declared, Sandra Hermann: None declared, Timo Gaber: None declared, Frank Buttgereit Grant/research support from: Amgen, BMS, Celgene, Generic Assays, GSK, Hexal, Horizon, Lilly, medac, Mundipharma, Novartis, Pfizer, Roche, and Sanofi.

scholarly journals Comparison of vitamin D profile between patients with inflammatory and non-inflammatory rheumatic diseases

2020 ◽  
Vol 62 (4) ◽  
pp. 254-259
Author(s):  
Nihan Cüzdan ◽  
İlke Coşkun Benlidayı ◽  
Sibel Başaran ◽  
Tunay Sarpel
Keyword(s):  
Vitamin D ◽  
Rheumatic Diseases ◽  
Inflammatory Rheumatic Diseases
Sign in / Sign up

Export Citation Format

Share Document